Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The primary aim is to assess the effects of raising HDL cholesterol (the good type) with
extended release niacin/laropiprant 2g (previously known as MK-0524A) versus matching placebo
on the risk of heart attack or coronary death, stroke, or the need for arterial bypass
procedures (revascularisation) in people with a history of circulatory problems. The
secondary aim is to assess the effects of extended release niacin/laropiprant 2g daily on
heart attack, coronary death, stroke, and revascularisation separately and to assess the
effects on mortality both overall and in various categories of causes of death, and of the
effects on major cardiovascular events in people with a history of different diseases at the
beginning of the study.
Phase:
Phase 3
Details
Lead Sponsor:
University of Oxford
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Ezetimibe Ezetimibe, Simvastatin Drug Combination Niacin Niacinamide Nicotinic Acids Simvastatin